Giancarla Fiori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giancarla Fiori has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Cristiano Crosta
European Institute of Oncology, Milan, Italy
3 shared publications - Cristina Trovato
Division of Endoscopy, European Institute of Oncology, Milan, Italy
3 shared publications - Davide Ravizza
Division of Endoscopy, European Institute of Oncology, IRCCS, Milan, Italy
3 shared publications Alberto Prada
Servizio Gastroenterologia ed Endoscopia Digestiva Istituto Auxologico Italiano Milan Italy
2 shared publications- Anna Orsatti
Medical Affairs, NTC Milan Italy
2 shared publications Bruno Mario Cesana
Statistics and Biomathematics Unit, Department of Molecular and Transactional Medicine Faculty of Medicine and Surgery University of Brescia Brescia Italy
2 shared publications
Latest Publications
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S191
Feasibility, safety and efficacy of partially covered self-expandable metal stents for leaks after esophageal or gastric resection for malignances: a single center experience
Aims to assess the feasibility, safety and efficacy of partially covered self-expandable metal stents (PC SEMS) for leaks after esophageal or gastric resection for malignances Methods we retrospectively collected data of patients from November 2018 to October 2022 Results 23 patients (18 M, median age 70 yrs) were included. 11 patients had an esophagogastric anastomosis, 11 an esophagojejunal anastomosis and 1 an esophago-colonic anastomosis. 22 defects were anastomotic leak, 1 was a leak of the jejunal cul-de-sac. The median time between surgery and leak diagnosis was 8 (3-44) days. 20 (87 %) patients received Boston Ultraflex partially covered stent (100/120/150 mmx18/23 mm) and 3 (13 %) patients Boston Agile partially covered stent (120/150x23 mm). Stent placement was technically successful in all patients. The median time between stent placement and removal was 29 (4-52) days. One patient died for other causes with stent in place. PC SEMS retrieval was safe and easy, except for one patient who needed stent-in-stent technique for the subsequent successful removal. 15/22 and 2/22 patients obtained leak resolution after one and two stent placement respectively, with an overall success rate of 77%. Concerning patients with persistent leak, 1 patient achieved defect healing with Esosponge, 4 (17%) patients needed reintervention. During a median follow-up time of 4.4 (1.1-35.2) months, complications were observed in 4/22 (18%) patients: 2 migrations, 1 stricture at the level of the proximal stent margin, 1 self-limiting haemorrage Conclusions PC SEMS placement is a feasible, safe and effective technique for leak treatment after esophageal or gastric surgery for malignances Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S191
Feasibility, safety and efficacy of partially covered self-expandable metal stents for leaks after esophageal or gastric resection for malignances: a single center experience
Aims to assess the feasibility, safety and efficacy of partially covered self-expandable metal stents (PC SEMS) for leaks after esophageal or gastric resection for malignances Methods we retrospectively collected data of patients from November 2018 to October 2022 Results 23 patients (18 M, median age 70 yrs) were included. 11 patients had an esophagogastric anastomosis, 11 an esophagojejunal anastomosis and 1 an esophago-colonic anastomosis. 22 defects were anastomotic leak, 1 was a leak of the jejunal cul-de-sac. The median time between surgery and leak diagnosis was 8 (3-44) days. 20 (87 %) patients received Boston Ultraflex partially covered stent (100/120/150 mmx18/23 mm) and 3 (13 %) patients Boston Agile partially covered stent (120/150x23 mm). Stent placement was technically successful in all patients. The median time between stent placement and removal was 29 (4-52) days. One patient died for other causes with stent in place. PC SEMS retrieval was safe and easy, except for one patient who needed stent-in-stent technique for the subsequent successful removal. 15/22 and 2/22 patients obtained leak resolution after one and two stent placement respectively, with an overall success rate of 77%. Concerning patients with persistent leak, 1 patient achieved defect healing with Esosponge, 4 (17%) patients needed reintervention. During a median follow-up time of 4.4 (1.1-35.2) months, complications were observed in 4/22 (18%) patients: 2 migrations, 1 stricture at the level of the proximal stent margin, 1 self-limiting haemorrage Conclusions PC SEMS placement is a feasible, safe and effective technique for leak treatment after esophageal or gastric surgery for malignances Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 17 February 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (5) , 759-769
Factors influencing the presence of potentially explosive gases during colonoscopy: Results of the SATISFACTION study
This study tested the hypothesis that bowel preparation with mannitol should not affect the colonic concentration of H2 and CH4. Therefore, the SATISFACTION study, an international, multicenter, randomized, parallel‐group phase II–III study investigated this issue. The phase II dose‐finding part of the study evaluated H2, CH4, and O2 concentrations in 179 patients randomized to treatment with 50 g, 100 g, or 150 g mannitol. Phase III of the study compared the presence of intestinal gases in 680 patients randomized (1:1) to receive mannitol 100 g in single dose or a standard split‐dose 2 L polyethylene glycol (PEG)‐Asc preparation (2 L PEG‐Asc). Phase II results showed that mannitol did not influence the concentration of intestinal gases. During phase III, no patient in either group had H2 or CH4 concentrations above the critical thresholds. In patients with H2 and/or CH4 levels above detectable concentrations, the mean values were below the risk thresholds by at least one order of magnitude. The results also highlighted the effectiveness of standard washing and insufflation maneuvers in removing residual intestinal gases. In conclusion, bowel cleansing with mannitol was safe as the concentrations of H2 and CH4 were the same as those found in patients prepared with 2 L PEG‐Asc. In both groups, the concentrations of gases were influenced more by the degree of cleansing achieved and the insufflation and washing maneuvers performed than by the preparation used for bowel cleansing. The trial protocol was registered with ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04759885) and with EudraCT (eudract_number: 2019‐002856‐18).
- 17 February 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (5) , 759-769
Open AccessFactors influencing the presence of potentially explosive gases during colonoscopy: Results of the SATISFACTION study
This study tested the hypothesis that bowel preparation with mannitol should not affect the colonic concentration of H2 and CH4. Therefore, the SATISFACTION study, an international, multicenter, randomized, parallel‐group phase II–III study investigated this issue. The phase II dose‐finding part of the study evaluated H2, CH4, and O2 concentrations in 179 patients randomized to treatment with 50 g, 100 g, or 150 g mannitol. Phase III of the study compared the presence of intestinal gases in 680 patients randomized (1:1) to receive mannitol 100 g in single dose or a standard split‐dose 2 L polyethylene glycol (PEG)‐Asc preparation (2 L PEG‐Asc). Phase II results showed that mannitol did not influence the concentration of intestinal gases. During phase III, no patient in either group had H2 or CH4 concentrations above the critical thresholds. In patients with H2 and/or CH4 levels above detectable concentrations, the mean values were below the risk thresholds by at least one order of magnitude. The results also highlighted the effectiveness of standard washing and insufflation maneuvers in removing residual intestinal gases. In conclusion, bowel cleansing with mannitol was safe as the concentrations of H2 and CH4 were the same as those found in patients prepared with 2 L PEG‐Asc. In both groups, the concentrations of gases were influenced more by the degree of cleansing achieved and the insufflation and washing maneuvers performed than by the preparation used for bowel cleansing. The trial protocol was registered with ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04759885) and with EudraCT (eudract_number: 2019‐002856‐18).
- Open Access
- 8 August 2022
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (10) , 2448-2457
Pharmacokinetics of oral mannitol for bowel preparation for colonoscopy
This study aimed to define the pharmacokinetics (PKs) of oral mannitol used as an osmotic laxative for bowel preparation for colonoscopy. The PKs of oral mannitol was evaluated in a substudy as part of a phase II dose‐finding, international, multicenter, randomized, parallel‐group, endoscopist‐blinded study. Patients were randomly assigned to take 50, 100, or 150 g mannitol. Venous blood samples were drawn at baseline (T0), 1 h (T1), 2 h (T2), 4 h (T4), and 8 h (T8) after completion of mannitol self‐administration. The mean mannitol plasma concentrations (mg/ml) were dose‐dependent with a consistent difference among doses. The mean maximum concentration (Cmax) ± SD was 0.63 ± 0.15, 1.02 ± 0.28, and 1.36 ± 0.39 mg/ml, in the three dosage groups, respectively. The mean area under the curve from zero to infinity (AUC0−∞) was 2.667 ± 0.668, 4.992 ± 1.706, and 7.403 ± 3.472 mg/ml*h in the 50, 100, and 150 g mannitol dose groups, respectively. Bioavailability was similar in the three dose groups and was just over 20% (0.243 ± 0.073, 0.209 ± 0.081, and 0.228 ± 0.093 in the 50, 100, and 150 g mannitol dose groups, respectively). The present study showed that the bioavailability of oral mannitol is just over 20% and is similar for the three tested doses (50, 100, and 150 g). The linear increase in Cmax, AUC0−t8, and AUC0−∞ must be considered when choosing the oral mannitol dose for bowel preparation to avoid its systemic osmotic effects.
- 8 August 2022
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (10) , 2448-2457
Open AccessPharmacokinetics of oral mannitol for bowel preparation for colonoscopy
This study aimed to define the pharmacokinetics (PKs) of oral mannitol used as an osmotic laxative for bowel preparation for colonoscopy. The PKs of oral mannitol was evaluated in a substudy as part of a phase II dose‐finding, international, multicenter, randomized, parallel‐group, endoscopist‐blinded study. Patients were randomly assigned to take 50, 100, or 150 g mannitol. Venous blood samples were drawn at baseline (T0), 1 h (T1), 2 h (T2), 4 h (T4), and 8 h (T8) after completion of mannitol self‐administration. The mean mannitol plasma concentrations (mg/ml) were dose‐dependent with a consistent difference among doses. The mean maximum concentration (Cmax) ± SD was 0.63 ± 0.15, 1.02 ± 0.28, and 1.36 ± 0.39 mg/ml, in the three dosage groups, respectively. The mean area under the curve from zero to infinity (AUC0−∞) was 2.667 ± 0.668, 4.992 ± 1.706, and 7.403 ± 3.472 mg/ml*h in the 50, 100, and 150 g mannitol dose groups, respectively. Bioavailability was similar in the three dose groups and was just over 20% (0.243 ± 0.073, 0.209 ± 0.081, and 0.228 ± 0.093 in the 50, 100, and 150 g mannitol dose groups, respectively). The present study showed that the bioavailability of oral mannitol is just over 20% and is similar for the three tested doses (50, 100, and 150 g). The linear increase in Cmax, AUC0−t8, and AUC0−∞ must be considered when choosing the oral mannitol dose for bowel preparation to avoid its systemic osmotic effects.
- 10 May 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (8) , 636-641
Linear array ultrasonography to stage rectal neoplasias suitable for local treatment
- 10 May 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (8) , 636-641
Linear array ultrasonography to stage rectal neoplasias suitable for local treatment
- 1 April 2008
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 67 (5) , AB97
Confocal Laser Endomicroscopy for in-vivo Diagnosis of Barrett's Esophagus and Associated Neoplasia: An Ongoing Prospective Study
- 1 April 2008
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 67 (5) , AB97
Confocal Laser Endomicroscopy for in-vivo Diagnosis of Barrett's Esophagus and Associated Neoplasia: An Ongoing Prospective Study